DOTA-EGFL6 peptide was radiolabeled with 111In and purified peptide was prepared at 1.85 MBq/mL in sterile PBS. Three mice bearing MDA-MB-435 tumors were intravenously injected with 111In-DOTA-EGFL6 and sacrificed at 2 h. Organs and tissues pertinent to tumor uptake and clearance were excised, weighed, and counted by gamma counter. Percentage of injected dose per gram (%ID/g) of tissue was reported to normalize uptake by tissue mass.
Radiolabeled, purified 111In-DOTA-GSG-EGFL6 was diluted to 11.1 MBq in 100 µL of sterile PBS. The peptide was injected intravenously in a mouse bearing an MDA-MB-435 human breast cancer xenograft. Following injection, radiolabeled peptide was permitted to circulate for 2h, followed by euthanization by carbon dioxide. The treated mouse was imaged at the Harry S. Truman Veterans Memorial Hospital Biomolecular Imaging Center. Overnight (7h) image acquisition was performed with a Siemens Inveon Micro-SPECT/CT (Siemens, Knoxville, TN) equipped with mouse whole body 1.0 mm collimators. Data were processed with Inveon Research Workplace processing software and fan beam (Feldkamp) filtered back projection algorithms were used for reconstruction of the CT tomographic image.
Radiolabeled, purified 111In-DOTA-GSG-EGFL6 was diluted to 11.1 MBq in 100 µL of sterile PBS. The peptide was injected intravenously in a mouse bearing an MDA-MB-435 human breast cancer xenograft. Following injection, radiolabeled peptide was permitted to circulate for 2h, followed by euthanization by carbon dioxide. The treated mouse was imaged at the Harry S. Truman Veterans Memorial Hospital Biomolecular Imaging Center. Overnight (7h) image acquisition was performed with a Siemens Inveon Micro-SPECT/CT (Siemens, Knoxville, TN) equipped with mouse whole body 1.0 mm collimators. Data were processed with Inveon Research Workplace processing software and fan beam (Feldkamp) filtered back projection algorithms were used for reconstruction of the CT tomographic image.